Occult progression by Apc-deficient intestinal crypts as a target for chemoprevention

Jared Fischer, Arnout G. Schepers, Hans Clevers, Darryl Shibata, Robert (Mike) Liskay

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Although Apc mutation is widely considered an initiating event in colorectal cancer, little is known about the earliest stages of tumorigenesis following sporadic Apc loss. Therefore, we have utilized a novel mouse model that facilitates the sporadic inactivation of Apc via frameshift reversion of Cre in single, isolated cells and subsequently tracks the fates of Apc-deficient intestinal cells. Our results suggest that consistent with Apc being a 'gatekeeper', loss of Apc early in life during intestinal growth leads to adenomas or increased crypt fission, manifested by fields of mutant but otherwise normal-appearing crypts. In contrast, Apc loss occurring later in life has minimal consequences, with mutant crypts being less prone to either increased crypt fission or adenoma formation. Using the stem cell-specific Lgr5-CreER mouse, we generated different sized fields of Apc-deficient crypts via independent recombination events and found that field size correlates with progression to adenoma. To evaluate this early stage prior to adenoma formation as a therapeutic target, we examined the chemopreventive effects of sulindac on Apc-deficient occult crypt fission. We found that sulindac treatment started early in life inhibits the morphologically occult spread of Apc-deficient crypts and thus reduces adenoma numbers. Taken together these results suggest that: (i) earlier Apc loss promotes increased crypt fission, (ii) a field of Apc-deficient crypts, which can form via occult crypt fission or independent neighboring events, is an important intermediate between loss of Apc and adenoma formation and (iii) normal-appearing Apc-deficient crypts are potential unappreciated targets for cancer screening and chemoprevention.

Original languageEnglish (US)
Pages (from-to)237-246
Number of pages10
JournalCarcinogenesis
Volume35
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Chemoprevention
Adenoma
Sulindac
Early Detection of Cancer
Genetic Recombination
Colorectal Neoplasms
Carcinogenesis
Stem Cells
Mutation
Therapeutics
Growth

ASJC Scopus subject areas

  • Cancer Research

Cite this

Occult progression by Apc-deficient intestinal crypts as a target for chemoprevention. / Fischer, Jared; Schepers, Arnout G.; Clevers, Hans; Shibata, Darryl; Liskay, Robert (Mike).

In: Carcinogenesis, Vol. 35, No. 1, 01.2014, p. 237-246.

Research output: Contribution to journalArticle

Fischer, Jared ; Schepers, Arnout G. ; Clevers, Hans ; Shibata, Darryl ; Liskay, Robert (Mike). / Occult progression by Apc-deficient intestinal crypts as a target for chemoprevention. In: Carcinogenesis. 2014 ; Vol. 35, No. 1. pp. 237-246.
@article{ca4b25979174444fb5c6551fb1dc354d,
title = "Occult progression by Apc-deficient intestinal crypts as a target for chemoprevention",
abstract = "Although Apc mutation is widely considered an initiating event in colorectal cancer, little is known about the earliest stages of tumorigenesis following sporadic Apc loss. Therefore, we have utilized a novel mouse model that facilitates the sporadic inactivation of Apc via frameshift reversion of Cre in single, isolated cells and subsequently tracks the fates of Apc-deficient intestinal cells. Our results suggest that consistent with Apc being a 'gatekeeper', loss of Apc early in life during intestinal growth leads to adenomas or increased crypt fission, manifested by fields of mutant but otherwise normal-appearing crypts. In contrast, Apc loss occurring later in life has minimal consequences, with mutant crypts being less prone to either increased crypt fission or adenoma formation. Using the stem cell-specific Lgr5-CreER mouse, we generated different sized fields of Apc-deficient crypts via independent recombination events and found that field size correlates with progression to adenoma. To evaluate this early stage prior to adenoma formation as a therapeutic target, we examined the chemopreventive effects of sulindac on Apc-deficient occult crypt fission. We found that sulindac treatment started early in life inhibits the morphologically occult spread of Apc-deficient crypts and thus reduces adenoma numbers. Taken together these results suggest that: (i) earlier Apc loss promotes increased crypt fission, (ii) a field of Apc-deficient crypts, which can form via occult crypt fission or independent neighboring events, is an important intermediate between loss of Apc and adenoma formation and (iii) normal-appearing Apc-deficient crypts are potential unappreciated targets for cancer screening and chemoprevention.",
author = "Jared Fischer and Schepers, {Arnout G.} and Hans Clevers and Darryl Shibata and Liskay, {Robert (Mike)}",
year = "2014",
month = "1",
doi = "10.1093/carcin/bgt296",
language = "English (US)",
volume = "35",
pages = "237--246",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Occult progression by Apc-deficient intestinal crypts as a target for chemoprevention

AU - Fischer, Jared

AU - Schepers, Arnout G.

AU - Clevers, Hans

AU - Shibata, Darryl

AU - Liskay, Robert (Mike)

PY - 2014/1

Y1 - 2014/1

N2 - Although Apc mutation is widely considered an initiating event in colorectal cancer, little is known about the earliest stages of tumorigenesis following sporadic Apc loss. Therefore, we have utilized a novel mouse model that facilitates the sporadic inactivation of Apc via frameshift reversion of Cre in single, isolated cells and subsequently tracks the fates of Apc-deficient intestinal cells. Our results suggest that consistent with Apc being a 'gatekeeper', loss of Apc early in life during intestinal growth leads to adenomas or increased crypt fission, manifested by fields of mutant but otherwise normal-appearing crypts. In contrast, Apc loss occurring later in life has minimal consequences, with mutant crypts being less prone to either increased crypt fission or adenoma formation. Using the stem cell-specific Lgr5-CreER mouse, we generated different sized fields of Apc-deficient crypts via independent recombination events and found that field size correlates with progression to adenoma. To evaluate this early stage prior to adenoma formation as a therapeutic target, we examined the chemopreventive effects of sulindac on Apc-deficient occult crypt fission. We found that sulindac treatment started early in life inhibits the morphologically occult spread of Apc-deficient crypts and thus reduces adenoma numbers. Taken together these results suggest that: (i) earlier Apc loss promotes increased crypt fission, (ii) a field of Apc-deficient crypts, which can form via occult crypt fission or independent neighboring events, is an important intermediate between loss of Apc and adenoma formation and (iii) normal-appearing Apc-deficient crypts are potential unappreciated targets for cancer screening and chemoprevention.

AB - Although Apc mutation is widely considered an initiating event in colorectal cancer, little is known about the earliest stages of tumorigenesis following sporadic Apc loss. Therefore, we have utilized a novel mouse model that facilitates the sporadic inactivation of Apc via frameshift reversion of Cre in single, isolated cells and subsequently tracks the fates of Apc-deficient intestinal cells. Our results suggest that consistent with Apc being a 'gatekeeper', loss of Apc early in life during intestinal growth leads to adenomas or increased crypt fission, manifested by fields of mutant but otherwise normal-appearing crypts. In contrast, Apc loss occurring later in life has minimal consequences, with mutant crypts being less prone to either increased crypt fission or adenoma formation. Using the stem cell-specific Lgr5-CreER mouse, we generated different sized fields of Apc-deficient crypts via independent recombination events and found that field size correlates with progression to adenoma. To evaluate this early stage prior to adenoma formation as a therapeutic target, we examined the chemopreventive effects of sulindac on Apc-deficient occult crypt fission. We found that sulindac treatment started early in life inhibits the morphologically occult spread of Apc-deficient crypts and thus reduces adenoma numbers. Taken together these results suggest that: (i) earlier Apc loss promotes increased crypt fission, (ii) a field of Apc-deficient crypts, which can form via occult crypt fission or independent neighboring events, is an important intermediate between loss of Apc and adenoma formation and (iii) normal-appearing Apc-deficient crypts are potential unappreciated targets for cancer screening and chemoprevention.

UR - http://www.scopus.com/inward/record.url?scp=84891361272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891361272&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgt296

DO - 10.1093/carcin/bgt296

M3 - Article

C2 - 23996931

AN - SCOPUS:84891361272

VL - 35

SP - 237

EP - 246

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 1

ER -